Bio CEO & Investor Conference
February 13-14, 2017
The Waldorf Astoria, New York, New York
The 19th Annual Bio CEO & Investor Conference in New York City brings together a lineup of biotech companies, public and private equity investors, and members of the sell-side investment community for a two-day event that provides insight into the current investment landscape and opportunities in life sciences. In addition to plenary sessions and panel discussions, the conference features presentations by over 175 leading biotech and pharmaceutical companies, as well as a number of non-profit and venture philanthropy organizations. For more information visit www.bio.org
Neurotrope (OTC: NTRP) is developing a novel therapy to treat and potentially reverse moderate to severe Alzheimer's disease and other neurodegenerative diseases. The company's world-class science is a paradigm shifting approach that treats some of the underlying causes of Alzheimer's disease. The scientific basis of its treatment is activation of Protein Kinase C isozymes and α by bryostatin, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's disease. For more information, visit the company's website at www.neurotropebioscience.com.
NovoCure (NASDAQ: NVCR) develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (TTFields). The company markets its proprietary TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It also conducts clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. NovoCure markets its products in the United States, as well as in European Union member states, Switzerland and Japan. For more information, visit the company's website at www.novocure.com.
OncoCyte (NYSE: OCX) focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using proprietary sets of genetic and protein markers expressed in various types of cancers. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder and breast cancers. The company was founded in 2009 and is based in Alameda, California. OncoCyte is a subsidiary of BioTime, Inc. For more information, visit the company's website at www.oncocyte.com.
OncoMed Pharmaceuticals (OMED)
OncoMed Pharmaceuticals (NASDAQ: OMED) discovers and develops novel anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The company's product candidates and preclinical programs include demcizumab, a humanized monoclonal antibody in two phase II clinical trials for non-small cell lung cancer and pancreatic cancer patients; tarextumab, which is in phase II clinical trial for small cell lung cancer patients; vantictumab, in two phase Ib clinical trials for breast cancer and pancreatic cancer patients; ipafricept, a fusion protein based Frizzled8 receptor or Fzd8, which is in two phase Ib clinical trials for pancreatic and ovarian cancer patients; and brontictuzumab targeting the Notch1 receptor, which completed phase Ia clinical trial in solid tumor patients. For more information, visit the company's website at www.oncomed.com.
Onconova Therapeutics (ONTX)
Onconova Therapeutics (NASDAQ: ONTX) is a phase 3 clinical stage biopharmaceutical company that focuses on discovering and developing innovative small molecule therapies for cancer. Through its proprietary chemistry platform, the company has designed a pipeline of targeted anti-cancer product candidates that work against specific cellular pathways important in cancer cells, with minimal damage to normal cells. Onconova's clinical stage therapies are based on its lead compound Rigosertib and are aimed at meeting the needs of patients with myeodysplastic syndromes. In addition to Rigosertib-based therapies, the company also has other product candidates in precinical development, targeting kinases, cellular metabolism, or cell division. For more information, visit the company's website at www.onconova.com.
OncoSec Medical (ONCS)
OncoSec Medical (NASDAQ: ONCS) develops and commercializes innovative gene therapies and technologies designed to stimulate the body's immune system to target and attack cancer. The company's proprietary technologies, including investigation platform ImmunoPulse®, are meant to deliver safer and more effective cancer treatments that can offer long-term benefits to patients across the United States. The ImmunoPulse® platform is an electroportation delivery device used together with the company's product candidates to deliver the treatment directly into the tumor and therefore trigger an anti-cancer inflammatory response. OncoSec's ImmunoPulse IL-12 candidate is currently undergoing phase II clinical trial for various types of cancer, such as metastatic melanoma and triple negative breast cancer. For more information, visit the company's website at www.oncosec.com.
Oramed Pharmaceuticals (ORMP)
Oramed Pharmaceuticals (NASDAQ: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The company completed multiple phase II clinical trials of ORMD-0801 under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901). For more information, visit the company's website at www.oramed.com.
Orexigen Therapeutics (OREX)
Orexigen Therapeutics (NASDAQ: OREX) is a biopharmaceutical company focused on the development of innovative obesity treatments. The company's first pharmaceutical product, Contrave®, is currently commercialized both in the United States and in Europe where it was approved under the brand name Mysimba®. In the U.S., Contrave® has become the most prescribed branded obesity medication since June 2015. Orexigen Therapeutics has signed partnerships with various other companies around the world so as to bring Contrave/Mysimba to as many patients as possible. It currently has a collaboration agreement with Takeda Pharmaceutical Company Limited (OTC: TKPYY) to develop and commercialize Contrave® in the United States, Canada and Mexico. For more information, visit the company's website at www.orexigen.com.
Palatin Technologies (PTN)
Palatin Technologies (NYSE: PTN) is a biopharmaceutical company that develops targeted, receptor-specific peptide therapeutics for various diseases. The company's therapies are based on molecules that modulate the activity of the natriuretic and melanocortin peptide receptor systems. Palatin Technologies' lead product candidate is Bremelanotide, a subcutaneous injection currently undergoing phase III clinical trials for the treatment of female sexual dysfunction – more specifically for premenopausal women diagnosed with hypoactive sexual desire disorder. The company is also developing other drug candidates for various ailments such as pulmonary diseases, heart failure, obesity, dermatological and inflammatory diseases, and erectile dysfunction. For more information, visit the company's website at www.palatin.com.
PhaseRx (NASDAQ: PZRX) is a biopharmaceutical company that engages in developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. Its initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The company's i-ERT approach is enabled by its proprietary Hybrid mRNA Technology platform and is applicable to various inherited liver diseases. PhaseRx's product pipeline includes PRX-OTC for Ornithine Transarbamylase deficiency; PRX-ASL for Argininosuccinate Lyase deficiency; and PRX-ASS1 for Argininosuccinatesynthetase 1 deficiency. For more information, visit the company's website at www.phaserx.com.
Pieris Pharmaceuticals (PIRS)
Pieris Pharmaceuticals (NASDAQ: PIRS) is a clinical stage biopharmaceutical company that discovers and develops Anticalin-based drugs. The company develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Pieris Pharmaceuticals primarily focuses on the development of three drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases; and PRS-343, a bispecific protein for oncology diseases. For more information, visit the company's website at www.pieris.com.
Progenics Pharmaceuticals (PGNX)
Progenics Pharmaceuticals (NASDAQ: PGNX) develops medicines for oncology in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in phase IIb clinical trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted PET imaging agent for prostate cancer. For more information, visit the company's website at www.progenics.com.
ProMetic Life Sciences (PFSCF)
ProMetic Life Sciences (OTC: PFSCF) is a biopharmaceutical company that develops bio separations, plasma-derived therapeutics, and small-molecule drugs. The company offers its technology platform for large-scale drug purification, drug development, proteomics and the elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, autoimmune disease/inflammation, and cancer. Under its Small Molecule Therapeutics segment, the company's lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of fibrosis in patients with chronic kidney diseases and certain cancers, and the side effects associated with chemotherapy. The Protein Technology segment provides Plasma Protein Purification System, a solution for plasma fractionation, as well as for the extraction and purification of therapeutic proteins from human plasma. For more information, visit the company's website at www.prometic.com.
RedHill Biopharma (RDHL)
RedHill Biopharma (NASDAQ: RDHL) is focused on the development and commercialization of late clinical-stage, proprietary and orally administered small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, and cancer. Its pipeline of products include RHB-105, an oral combination therapy for the treatment of helicobacter pylori infection, which has completed phase III study; RHB-104, an oral combination therapy for the treatment of Crohn's disease with an ongoing first phase III study, as well as in proof-of-concept phase IIa study for multiple sclerosis; and BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron that is in phase III study in the U.S. for acute gastroenteritis and gastritis, as well as in phase II study for IBS-D. For more information, visit the company's website at www.redhillbio.com.
Relmada Therapeutics (RLMD)
Relmada Therapeutics (NYSE: RLMD) is a clinical-stage biotechnology company focused on developing drugs to treat central nervous system (CNS) diseases, primarily depression and chronic pain in the United States. Its lead product candidate, d-Methadone, is being developed for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. The company is also developing LevoCap ER for the management of pain; BuTab ER, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence indications; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy. For more information, visit the company's website at www.relmada.com.
RespireRx Pharmaceuticals (RSPI)
RespireRx Pharmaceuticals (OTC: RSPI) engages in the discovery and development of drugs for the treatment of respiratory disorders. The company has two drug platforms comprising ampakines that act as positive allosteric modulators of AMPA glutamate receptors; and cannabinoids, primarily dronabinol, a synthetic derivative for use in refractory chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS. It develops various ampakines in oral and injectable form for the treatment of various breathing disorders. The company's lead ampakine, CX1739, has completed phase I clinical studies for drug-induced respiratory depression, and is also in phase I clinical studies for central sleep apnea. For more information, visit the company's website at www.respirerx.com.
Resverlogix (OTC: RVX) is a clinical-stage biotechnology company that develops small molecule therapeutics for Bromodomain and ExtraTerminal (BET) inhibition. The company's apabetalone (RVX-208) is in clinical trials for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, Alzheimer's disease, and orphan diseases. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. For more information, visit the company's website at www.resverlogix.com.
RXi Pharmaceuticals (RXII)
RXi Pharmaceuticals (NASDAQ: RXII) is a clinical-stage RNAi company that focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. Its clinical development programs include RXI-109, a self-delivering RNAi compound in phase IIa clinical trial for prevention or reduction of dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids, and in a phase I/II clinical trial in retinal scarring. RXi is also developing RXI-109 for the treatment of an ophthalmic indication, focusing on retinal and corneal scarring; and Samcyprone, in phase II clinical trial for the treatment of various disorders, such as warts, alopecia areata, non-malignant skin tumors, and cutaneous metastases of melanoma. For more information, visit the company's website at www.rxipharma.com.
Sierra Oncology (SRRA)
Sierra Oncology (NASDAQ: SRRA) is a clinical-stage drug development company developing DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer. Its lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a key cell cycle checkpoint and central regulator of the DDR network. The company is also developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase undergoing preclinical development. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. For more information, visit the company's website at www.sierraoncology.com.
Sonoma Pharmaceuticals (SNOA)
Sonoma Pharmaceuticals (NASDAQ: SNOA) designs, produces and markets prescription and over-the-counter products based on its Microcyn platform technology for the dermatology, surgical, advanced tissue, skincare and animal healthcare markets in the United States, Latin America, Europe and rest of the world. The Microcyn platform technology is based on electrically charged oxychlorine small molecules, which are designed to target a range of pathogens that cause disease, including viruses, fungi, spores and bacteria such as antibiotic-resistant strains. It also provides consulting and laboratory services to medical companies that design and manufacture biomedical devices and drugs. For more information, visit the company's website at www.sonomapharma.com.
Sorrento Therapeutics (SRNE)
Sorrento Therapeutics (NASDAQ:SRNE) is a biopharmaceutical company engaged in the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs worldwide. The company's primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. The company currently has multiple clinical development programs underway: (i) CAR-T programs for solid tumors, (ii) resiniferatoxin, or RTX, a non-opiate, ultra-potent and selective agonist of the TRPV-1 receptor for intractable pain in end-stage disease, and (iii) biosimilar/biobetter antibodies clinical development programs. For more information, visit the company's website at www.sorrentotherapeutics.com.
Spotlight Innovation (STLT)
Spotlight Innovation (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, the company leverages its extensive relationships with leading scientists, academic institutions and other sources. It provides value-added capability to accelerate development progress. When scientifically significant benchmarks have been achieved, Spotlight will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit the company's website at www.spotlightinnovation.com.
Spring Bank Pharmaceuticals (SBPH)
Spring Bank Pharmaceuticals (OTC: SBPH) is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus. SB 9200 has been designed to selectively activate within infected cells the cellular proteins, retinoic acid-inducible gene 1, or RIG-I, and nucleotide-binding oligomerization domain-containing protein 2, or NOD2, which have been implicated in the body's immune response to viral infections. For more information, visit the company's website at www.springbankpharm.com.
Summit Therapeutics (SUMM)
Summit Therapeutics (OTC: SUMM) is a biopharmaceutical company that focuses on the discovery, development, and commercialization of medicines to treat genetic and infectious diseases in the United Kingdom and North America. The company is developing Ezutromid, an utrophin modulator product candidate that is in phase II clinical trials used for to treat Duchenne muscular dystrophy disease; and Ridinilazole, an orally administered small molecule antibiotic, which is in phase II clinical trials for the treatment of Clostridium difficile infection disease. It has strategic alliance with the University of Oxford to develop utrophin modulators. For more information, visit the company's website at www.summitplc.com.
Sunesis Pharmaceuticals (SNSS)
Sunesis Pharmaceuticals (NASDAQ: SNSS) is focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome; developing SNS-062, a non-covalently binding inhibitor of the human protein Bruton's tyrosine kinase. For more information, visit the company's website at www.sunesis.com.
Syndax Pharmaceuticals (SNDX)
Syndax Pharmaceuticals (NASDAQ: SNDX) is a late-stage biopharmaceutical company focused on the development and commercialization of therapeutics in oncology. The company's lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. Syndax has a collaborative research and development agreement with the National Cancer Institute, as well as Genentech. For more information, visit the company's website at www.syndax.com.
Synthetic Biologics (SYN)
Synthetic Biologics (NYSE: SYN) is a clinical-stage company that engages in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases in the United States. Its lead product candidates in phase II clinical trials include SYN-010, a formulation of lovastatin lactone to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-004, an oral prophylactic therapy for the prevention of C. difficile infections (CDI) and antibiotic-associated diarrhea (AAD). The company is also developing SYN-007 and SYN-006 for the prevention of CDI and AAD; SYN-005, a monoclonal antibody therapy for the prevention and treatment of pertussis; SYN-200 for the treatment of phenylketonuria; and SYN-020, an oral dosage form of intestinal alkaline phosphatase to preserve gut microbiome and barrier, as well as to treat inflammation. For more information, visit the company's website at www.syntheticbiologics.com.
Syros Pharmaceuticals (SYRS)
Syros Pharmaceuticals (NASDAQ: SYRS) is developing treatments for cancer and immune-mediated diseases, building a pipeline of gene control medicines. The company intends to begin a phase II clinical trial for its lead product candidate, SY-1425 (tamibarotene); and to initiate a phase I/II clinical trial for its SY-1365 candidate, initially for the treatment of acute leukemia. Formerly known as LS22, Inc., Syros Pharmaceuticals was founded in 2011 and is based in Cambridge, Massachusetts. For more information, visit the company's website at www.syros.com.
TG Therapeutics (TGTX)
TG Therapeutics (NASDAQ: TGTX) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. It develops TG-1101, a novel glycol engineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform. For more information, visit the company's website at www.tgtherapeutics.com.
ThromboGenics NV (TBGNF)
ThromboGenics NV (OTC: TBGNF) is an integrated biopharmaceutical company that develops and commercializes medicines that address unmet clinical needs in ophthalmology internationally. The company's lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. It has research and development agreements with BioInvent International AB to develop Anti-PlGF, a product candidate to treat Medulloblastoma, a pediatric malignant brain tumor; Eleven Biotherapeutics and Bicycle Therapeutics to develop and commercialize products for the treatment of eye diseases with diabetics; and Chilltern International, Inc. and Outcome Sciences, Inc., as well as Parexel to provide clinical research services for the development of JETREA. For more information, visit the company's website at www.thrombogenics.com.
TiGenix NV (TGXSF)
TiGenix NV (OTC: TGXSF) is a biopharmaceutical company that develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases. The company is developing Cx601, which is in phase III clinical trials for the treatment of complex perianal fistulas in patients suffering from Crohn's disease; Cx611, a clinical stage product candidate from its eASC-based technology platform, which completed a phase I study in sepsis and a phase I/IIa trial for the treatment of refractory rheumatoid arthritis; and Cx621, which has completed a phase I trial for the treatment of intra lymphatic administration of allogeneic eASCs. For more information, visit the company's website at www.tigenix.com.
Vascular Biogenics (VBLT)
Vascular Biogenics (NADAQ: VBLT) is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases in Israel. Its lead product candidate, VB-111, is a gene-based biologic in phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; in phase II clinical trials to treat thyroid cancer; and in phase II clinical trials for the treatment of ovarian cancer. The company's pipeline also incluces VB-511, an anti-angiogenic candidate for oncology; and VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases. For more information, visit the company's website at www.vblrx.com.
Vaxil Bio (VXLLF)
Vaxil Bio (OTC: VXLLF) is a clinical-stage biotechnology company engaged in the development of novel, immunotherapeutic products, peptides and antibodies for the treatment of cancer and infectious diseases. The company's lead product is ImMucin, a multi-epitope cancer vaccine to the MUC1 tumor associated antigen that completed phase II clinical trials; and is in phase I/II clinical trials for the treatment of metastatic breast cancer patients in combination with hormonal therapy. It also develops MTbuVax, a multi-antigenic and multi-epitope subunit vaccine, which is in preclinical stage to treat intracellular pathogenic bacteria mycobacterium tuberculosis. For more information, visit the company's website at www.vxlbio.com.
Verastem (NASDAQ: VSTM) is a biopharmaceutical company focused on discovering and developing drugs targeting cancer stem cells (CSCs). Its programs target the focal adhesion kinase (FAK) and the PI3K/mTOR signaling pathways. Among other candidates, the company's FAK inhibitor, VS-6063, is in phase I study in combination with PD-1 inhibitor pembrolizumab and gemcitabine for pancreatic cancer; a phase Ib clinical trial in combination with paclitaxel for patients with ovarian cancer; a phase II study in patients with non-small cell lung cancer; a phase II trial preceding surgery in mesothelioma; and a phase 1/1b clinical trial in combination with avelumab in patients with ovarian cancer, as well as a combination trial of VS-6063 and VS-5584 in patients with relapsed mesothelioma. For more information, visit the company's website at www.verastem.com.
Vical Inc. (VICL)
Vical Inc. (NASDAQ: VICL) engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Among other candidates in its pipeline, the company's candidates include a Vaxfectin®-formulated vaccine called CyMVectin™, which is intended to elicit immunity to CMV in women before they become pregnant, thereby reducing the possibility of transmitting CMV to the fetus during pregnancy. The company has designed a phase 1 trial of CyMVectin™, and the Investigational New Drug application has been allowed by the FDA. Vical is also developing the ASP0113 CMV Vaccine, HSV-2Therapeutic Vaccine, and VL-2397 Antifungal. For more information, visit the company's website at www.vical.com.
Viking Therapeutics (VKTX)
Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company that focuses on the development of therapies for metabolic and endocrine disorders. The company's lead clinical program includes VK0612, an orally available drug candidate for the treatment of Type 2 diabetes. The company is also developing VK5211, an orally available drug candidate in a phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery; VK0214, a novel liver-selective thyroid hormone receptor beta agonist for lipid disorders, such as dyslipidemia and nonalcoholic steatohepatitis; and VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor that is entering phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. For more information, visit the company's website at www.vikingtherapeutics.com.